Fundamental Analysis of Krebs Biochemicals & Industries Ltd

About the Company - Krebs Biochemicals & Industries Ltd

Krebs Biochemicals & Industries Ltd. is a Public Limited Listed company incorporated on 02/12/1991 and has its registered office in the State of Andhra Pradesh, India. Company’s Corporate Identification Number(CIN) is L24110AP1991PLC103912 and registration number is 103912. Currently company belongs to the Industry of Pharmaceuticals. Company’s Total Operating Revenue is Rs. 59.70 Cr. and Equity Capital is Rs. 21.56 Cr. for the Year ended 31/03/2022.

INDUSTRY	ADDRESS	CONTACT
Pharmaceuticals	Kothapalli Village, Anakapalli Dist. Andhra Pradesh 531031	investors@krebsbiochem.com http://www.krebsbiochem.com

Management
Name	Position Held
Dr. R T Ravi	Chairman & Non-Exe.Director
Mr. Jitendra Shah	Managing Director & CEO
Mr. Pabitrakumar Kalipada Bhattacharyya	Non Executive Director
Mr. Avinash Ravi	Non Executive Director
Mr. G V L Prasad	Independent Director
Mr. Raj Kamal Prasad Verma	Independent Director
Dr. Tangirala Malati	Independent Director
Mr. Satish Khivsara	Independent Director

Basic Stock Data of Krebs Biochemicals & Industries Ltd

Last Updated: July 27, 2024, 1:33 pm

Market Cap	204 Cr.
Current Price	94.5
High / Low	122/60.0
Stock P/E
Book Value	55.3
Dividend Yield	0.00 %
ROCE	19.0 %
ROE	%
Face Value	10.0
PEG Ratio	0.00

Data Source: screener.in

Competitors of Krebs Biochemicals & Industries Ltd

Stock Name	Market Cap	Current Price	High / Low	Stock P/E	Book Value	Dividend Yield	ROCE	ROE	Face Value
Murae Organisor Ltd	35.8 Cr.	1.45	3.10/0.90	717	2.26	0.00 %	0.79 %	0.13 %	2.00
Dipna Pharmachem Ltd	18.6 Cr.	7.73	24.1/7.46	17.1	15.6	0.00 %	8.49 %	4.47 %	10.0
Desh Rakshak Aushdhalaya Ltd	4.53 Cr.	10.2	10.2/6.31	10.5	21.4	0.00 %	6.75 %	4.62 %	10.0
Decipher Labs Ltd	18.5 Cr.	18.3	25.8/14.4		21.6	0.00 %	4.30 %	7.46 %	10.0
Coral Laboratories Ltd	255 Cr.	715	748/245	16.0	497	0.00 %	12.6 %	9.58 %	10.0
Industry Average	22,362.13 Cr	1,355.43		60.42	206.76	0.34%	17.28%	16.85%	6.48

Krebs Biochemicals & Industries Ltd Quarterly Results

Month	Dec 2020	Mar 2021	Jun 2021	Sep 2021	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023
Sales	9.58	15.86	6.76	11.98	21.81	19.16	10.64	20.94	9.09	11.46	10.58	14.89	12.98
Expenses	15.23	20.38	13.29	19.76	31.71	28.94	16.91	22.84	12.07	16.08	13.20	15.79	15.07
Operating Profit	-5.65	-4.52	-6.53	-7.78	-9.90	-9.78	-6.27	-1.90	-2.98	-4.62	-2.62	-0.90	-2.09
OPM %	-58.98%	-28.50%	-96.60%	-64.94%	-45.39%	-51.04%	-58.93%	-9.07%	-32.78%	-40.31%	-24.76%	-6.04%	-16.10%
Other Income	0.06	0.44	0.03	0.13	0.20	0.79	0.13	0.27	0.02	0.19	0.04	0.17	0.03
Interest	1.43	1.49	1.51	1.78	1.82	0.28	0.30	0.74	0.90	1.03	1.10	1.13	1.19
Depreciation	1.24	1.41	1.42	1.42	1.42	2.05	1.69	1.69	1.69	1.48	1.65	1.71	1.73
Profit before tax	-8.26	-6.98	-9.43	-10.85	-12.94	-11.32	-8.13	-4.06	-5.55	-6.94	-5.33	-3.57	-4.98
Tax %	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Profit	-8.26	-6.99	-9.42	-10.85	-12.94	-11.31	-8.14	-4.06	-5.55	-6.94	-5.33	-3.57	-4.98
EPS in Rs	-4.21	-3.56	-4.37	-5.03	-6.00	-5.25	-3.78	-1.88	-2.57	-3.22	-2.47	-1.66	-2.31

Last Updated: July 13, 2024, 6:19 pm

Krebs Biochemicals & Industries Ltd Quarterly Chart

Krebs Biochemicals & Industries Ltd Profit & Loss

Last Updated: July 10, 2024, 7:09 pm

Month	Mar 2012	Jun 2013	Sep 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	TTM
Sales	69	11	0	0	1	3	34	48	33	54	60	52	50
Expenses	73	24	4	5	14	11	41	58	52	71	94	68	60
Operating Profit	-4	-13	-4	-5	-12	-8	-8	-10	-19	-18	-34	-16	-10
OPM %	-5%	-117%			-1,088%	-248%	-22%	-20%	-56%	-33%	-57%	-30%	-20%
Other Income	3	6	0	3	1	-0	-1	0	0	1	1	1	0
Interest	9	1	0	4	1	3	5	6	6	6	5	3	4
Depreciation	10	8	0	2	4	4	4	4	5	5	6	7	7
Profit before tax	-19	-16	-4	-8	-16	-16	-18	-20	-29	-28	-45	-25	-21
Tax %	10%	5%	-10%	0%	0%	0%	0%	0%	0%	0%	0%	0%
Net Profit	-17	-15	-4	-8	-16	-16	-18	-20	-29	-28	-45	-25	-21
EPS in Rs	-15.17	-13.22	-3.78	-6.82	-10.33	-9.67	-10.73	-12.03	-16.04	-14.45	-20.65	-11.45	-9.66
Dividend Payout %	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%

Krebs Biochemicals & Industries Ltd Profit & Loss Yearly Chart

Krebs Biochemicals & Industries Ltd Growth

Compounded Sales Growth
10 Years:	16%
5 Years:	1%
3 Years:	-2%
TTM:	-3%

Compounded Profit Growth
10 Years:	-3%
5 Years:	0%
3 Years:	9%
TTM:	20%

Stock Price CAGR
10 Years:	13%
5 Years:	6%
3 Years:	-7%
1 Year:	45%

Return on Equity
10 Years:	%
5 Years:	%
3 Years:	%
Last Year:	%

Last Updated: July 24, 2024, 5:32 pm

Krebs Biochemicals & Industries Ltd Balance Sheet

Last Updated: July 10, 2024, 7:09 pm

Month	Mar 2012	Jun 2013	Sep 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Sep 2023
Equity Capital	10	10	10	10	13	14	14	17	18	20	22	22	22
Reserves	14	-2	-6	5	-4	-12	-32	-31	-43	-67	-97	-121	-130
Preference Capital	0	0	0	0	0	0	0	0	30	30	130	130
Borrowings	86	93	93	61	31	48	56	53	36	81	13	53	188
Other Liabilities	39	37	41	33	77	73	87	103	123	125	252	221	99
Total Liabilities	149	138	138	108	116	122	126	142	134	159	190	175	178
Fixed Assets	65	51	58	58	93	102	101	101	105	118	139	147	154
CWIP	0	7	0	0	11	4	4	3	4	12	8	4	0
Investments	0	0	0	0	0	0	0	0	0	0	0	0	0
Other Assets	83	80	80	50	13	16	21	38	24	29	43	24	24
Total Assets	149	138	138	108	116	122	126	142	134	159	190	175	178

Krebs Biochemicals & Industries Ltd Reserves and Borrowings Chart

Krebs Biochemicals & Industries Ltd Cash Flow

Month	Jun 2013	Sep 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Cash from Operating Activity	-2	49	-45	-15	-11	-6	4	-36	-15	-17	-25	2
Cash from Investing Activity	6	0	-3	-4	-5	-3	-4	-10	-23	-23	-13	-8
Cash from Financing Activity	-4	-49	54	13	16	9	17	29	38	40	37	6
Net Cash Flow	-0	0	6	-6	-0	0	17	-17	1	-1	-0	0

Krebs Biochemicals & Industries Ltd Financial Efficiency Indicators

Month	Mar 2012	Jun 2013	Sep 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023
Debtor Days	41	30			10	180	3	22	2	2	5	4
Inventory Days	286	2,368			14,704	2,162	337	142	345	234	230	170
Days Payable	256	1,517			32,250	4,360	510	339	521	292	340	217
Cash Conversion Cycle	70	881			-17,536	-2,018	-170	-175	-174	-57	-106	-44
Working Capital Days	-6	-446			-6,532	-2,132	-275	-315	-267	-119	-200	-162
ROCE %	-9%	-15%	-4%	-8%	-27%	-27%	-26%	-36%	-57%	-42%	-59%	-29%

Krebs Biochemicals & Industries Ltd Financial Efficiency Indicators Chart

Krebs Biochemicals & Industries Ltd Share Holding Pattern

Month	Jun 2021	Sep 2021	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024
Promoters	72.74%	72.74%	72.74%	72.74%	72.74%	72.74%	72.72%	72.74%	72.74%	72.74%	72.74%	72.74%
FIIs	0.01%	0.01%	0.01%	0.01%	0.01%	0.01%	0.33%	0.50%	0.50%	0.50%	0.50%	0.50%
Public	27.25%	27.25%	27.25%	27.25%	27.25%	27.26%	26.95%	26.76%	26.77%	26.76%	26.77%	26.75%
No. of Shareholders	7,096	8,571	8,166	9,531	9,533	9,650	9,294	9,315	9,393	9,030	8,990	8,909

Krebs Biochemicals & Industries Ltd Shareholding Pattern Chart

No. of Krebs Biochemicals & Industries Ltd Shareholders

This stock is not held by any mutual fund

Krebs Biochemicals & Industries Ltd ROCE Trend

Krebs Biochemicals & Industries Ltd EPS Trend

Krebs Biochemicals & Industries Ltd Key Financial Ratios

Month	Mar 24	Mar 23	Mar 22	Mar 21	Mar 20
FaceValue	10.00	10.00	10.00	10.00	10.00
Basic EPS (Rs.)	-9.16	-11.30	-20.81	-14.53	-16.75
Diluted EPS (Rs.)	-9.16	-11.30	-20.81	-14.53	-17.90
Cash EPS (Rs.)	-6.01	-8.41	-17.73	-11.84	-13.44
Book Value[Excl.RevalReserv]/Share (Rs.)	-55.29	-46.13	-34.83	-21.78	-13.89
Book Value[Incl.RevalReserv]/Share (Rs.)	-55.29	-46.13	-34.83	-21.78	-13.89
Revenue From Operations / Share (Rs.)	23.39	24.18	27.69	27.37	18.56
PBDIT / Share (Rs.)	-3.84	-7.03	-15.23	-8.64	-10.15
PBIT / Share (Rs.)	-6.97	-10.07	-18.15	-11.25	-12.75
PBT / Share (Rs.)	-9.15	-11.45	-20.65	-14.45	-16.04
Net Profit / Share (Rs.)	-9.15	-11.45	-20.65	-14.45	-16.04
PBDIT Margin (%)	-16.40	-29.07	-55.00	-31.57	-54.66
PBIT Margin (%)	-29.82	-41.65	-65.55	-41.11	-68.67
PBT Margin (%)	-39.12	-47.36	-74.58	-52.80	-86.41
Net Profit Margin (%)	-39.12	-47.36	-74.58	-52.80	-86.41
Return on Capital Employeed (%)	-12.92	-17.25	-35.02	-19.88	-25.30
Return On Assets (%)	-11.07	-14.11	-23.45	-17.81	-21.57
Long Term Debt / Equity (X)	-1.54	-0.43	-0.03	-2.35	-2.62
Total Debt / Equity (X)	-1.62	-0.53	-0.17	-2.35	-2.62
Asset Turnover Ratio (%)	0.28	0.28	0.34	0.36	0.24
Current Ratio (X)	0.28	0.32	0.45	0.44	0.43
Quick Ratio (X)	0.12	0.08	0.12	0.09	0.08
Inventory Turnover Ratio (X)	0.49	0.81	2.19	1.62	1.60
Interest Coverage Ratio (X)	-1.76	-5.10	-6.09	-2.70	-3.08
Interest Coverage Ratio (Post Tax) (X)	-3.21	-7.30	-7.26	-3.52	-3.87
Enterprise Value (Cr.)	324.85	304.75	451.99	274.16	212.76
EV / Net Operating Revenue (X)	6.44	5.85	7.57	5.11	6.37
EV / EBITDA (X)	-39.27	-20.10	-13.76	-16.17	-11.65
MarketCap / Net Operating Revenue (X)	2.61	2.33	5.18	3.25	4.41
Price / BV (X)	-1.10	-1.22	-4.12	-4.08	-5.90
Price / Net Operating Revenue (X)	2.61	2.33	5.18	3.25	4.41
EarningsYield	-0.14	-0.20	-0.14	-0.16	-0.19

Krebs Biochemicals & Industries Ltd Profitability Ratios (%)

Krebs Biochemicals & Industries Ltd Liquidity Ratios

Krebs Biochemicals & Industries Ltd Liquidity Ratios (%)

Krebs Biochemicals & Industries Ltd Interest Coverage Ratios (%)

Krebs Biochemicals & Industries Ltd Valuation Ratios

Fair Value

Fair Value: 126.91

Calculation basis:

Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

Undervalued: 34.30% compared to the current price 94.5

Default values used*: Deafault value of 15 for Stock P/E is used, Deafault value of 15% for ROE is used

Intrinsic Value: 189.29

Calculation basis:

Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators along with EPS growth.

Undervalued: 100.30% compared to the current price 94.5

Default values used*: Deafault value of 15 for Stock P/E is used, Deafault value of 15% for ROE is used

Last 5 Year EPS CAGR: 49.15%

*Investments are subject to market risks

Strength and Weakness of Krebs Biochemicals & Industries Ltd Stock

Strength	Weakness
The stock has a low average Working Capital Days of -149.83, which is a positive sign.	The stock has a low average ROCE of -28.25%, which may not be favorable. The stock has a high average Cash Conversion Cycle of 17.17, which may not be favorable. The company has higher borrowings (94.25) compared to reserves (-45.92), which may suggest financial risk. The company has not shown consistent growth in sales (31.92) and profit (-20.38).

FAQ

What is the latest fair value of Krebs Biochemicals & Industries Ltd?

The latest fair value of Krebs Biochemicals & Industries Ltd is ₹126.91.

What is the Market Cap of Krebs Biochemicals & Industries Ltd?

The Market Cap of Krebs Biochemicals & Industries Ltd is 204 Cr..

What is the current Stock Price of Krebs Biochemicals & Industries Ltd as on 27 July 2024?

The current stock price of Krebs Biochemicals & Industries Ltd as on 27 July 2024 is 94.5.

What is the High / Low of Krebs Biochemicals & Industries Ltd stocks in FY 2024?

In FY 2024, the High / Low of Krebs Biochemicals & Industries Ltd stocks is 122/60.0.

What is the Stock P/E of Krebs Biochemicals & Industries Ltd?

The Stock P/E of Krebs Biochemicals & Industries Ltd is .

What is the Book Value of Krebs Biochemicals & Industries Ltd?

The Book Value of Krebs Biochemicals & Industries Ltd is 55.3.

What is the Dividend Yield of Krebs Biochemicals & Industries Ltd?

The Dividend Yield of Krebs Biochemicals & Industries Ltd is 0.00 %.

What is the ROCE of Krebs Biochemicals & Industries Ltd?

The ROCE of Krebs Biochemicals & Industries Ltd is 19.0 %.

What is the ROE of Krebs Biochemicals & Industries Ltd?

The ROE of Krebs Biochemicals & Industries Ltd is %.

What is the Face Value of Krebs Biochemicals & Industries Ltd?

The Face Value of Krebs Biochemicals & Industries Ltd is 10.0.